Quantcast

Industry news that matters to you.  Learn more

Saladax Biomedical Laboratories to Offer the Full Portfolio of MyCare Therapeutic Dose Management Assays in the United States

Saladax Biomedical, Inc., a privately held company developing and commercializing novel diagnostic assays to achieve the promise of personalized medicine, recently announced that the My5-FU™ Assay will be part of the Saladax Biomedical Laboratories MyCare™ service offering when the CLIA laboratory located in Bethlehem, PA commences operations later this year.

My5-FU is a simple blood test that provides oncologists with objective information to guide optimized dosing of 5-fluorouracil (5-FU), controlling toxic side effects and improving treatment efficacy for cancer patients. The test has been offered in the United States by Myriad Genetics, Inc. under the trade name OnDose®, but rights to this assay will revert to Saladax when the Saladax Biomedical CLIA lab becomes operational in June 2013.

“We’re extremely pleased to bring our entire line of MyCare™ oncology therapeutic dose management assays under one roof,” said Kevin Harter , CEO & President of Saladax. “With the creation of the Saladax Biomedical Laboratories, cancer patients in the US can be better served with a single source for all oncology dose management testing services.”

“The CLIA laboratory expands the business model beyond the supply of diagnostic reagent kits in other markets of the world to include a clinical testing service for the US market. Saladax can provide assistance to cancer patients through channels best suited in specific markets,” added Mark D. Myslinski , Senior VP and Chief Commercial Officer.

Saladax Biomedical Laboratories will initially be offering testing services for MyPaclitaxel™ and MyDocetaxel™, as well as My5-FU™, and the menu will be further expanded with an additional 10 oncology dose management assays as their development is completed. The MyCare technology platform offers automated, rapid, robust and cost-effective blood tests for patient-specific chemotherapy dose optimization. These tests enable a physician to determine the optimal treatment effectiveness/toxicity balance for each unique patient.

OnDose will continue to be promoted and sold by Myriad through June, when the Saladax Biomedical Laboratories becomes operational and the customer base is transitioned to Saladax.

Source: Saladax Biomedical

Saladax Biomedical, Inc. Expands Distribution of MyCare™ Products in Israel

Saladax Biomedical, Inc., a privately held company developing and commercializing novel diagnostic assays to achieve the promise of personalized medicine for new and existing therapeutics, announced yesterday that Ilex Medical Ltd. will serve as exclusive distributor of Saladax’s My5-FU™, MyPaclitaxel™ and MyDocetaxel™ diagnostic reagent kits throughout the Israeli market. The MyCare™ tests are designed to measure levels of these common chemotherapy drugs in the blood of cancer patients to overcome the limitations associated with dosing based on body surface area (BSA).

Saladax Biomedical, Inc. Extends Availability of its MyCare Portfolio in Europe

Saladax Biomedical, Inc., a privately held company developing and commercializing novel diagnostic assays to achieve the promise of personalized medicine for new and existing therapeutics, recently announced the company has achieved CE mark registration for its MyPaclitaxel and MyDocetaxel therapeutic dose management (TDM) MyCare assays, enabling commercialization in the European Union (EU).

Saladax Biomedical, Inc. Expands Distribution of My5-FU in Spain and Portugal

Saladax Biomedical, Inc., a privately held company developing and commercializing novel diagnostic assays to achieve the promise of personalized medicine for new and existing therapeutics, announced today it has entered into a distribution agreement with INyDIA Labs, based in Madrid, Spain, for My5-FU, a test that measures levels of a widely-used anti-cancer drug, 5-fluorouracil (5-FU), in the blood of cancer patients.